Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer

Tejpar, Sabine; Stintzing, Sebastian; Ciardiello, Fortunato; Tabernero, Josep; Cutsem, Éric Van; Beier, Frank; Esser, Regina; Lenz, Heinz‐Josef; Heinemann, Volker

doi:10.1001/jamaoncol.2016.3797

Cited by 574 publications

(488 citation statements)

References 26 publications

Supporting

Mentioning

427

Contrasting

Unclassified

Order By: Relevance

“…Notably, while KRAS mutations (including codon 12 and 13) were not associated with the location of primary tumor, codon 13 mutation (G13D) itself was likely to occur in the tumors arising from right-sided colon. Recently, it was accepted that patients with right-sided colon cancer experienced an inferior OS rate (24). Additionally, increasing evidence suggests that mutations in KRAS codon 13 predict a poor outcome (12,18).…”

Section: Discussionmentioning

confidence: 99%

Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. KRAS mutations serve a function in tumorigenesis of colorectal cancer (CRC) and guide the use of targeted drugs. However, the prognostic value of KRAS mutations and their subtypes remain controversial. The present study aimed to investigate the correlations between KRAS mutations and clinicopathological characteristics, and their prognostic significance in Chinese patients with metastatic CRC (mCRC). A total of 135 patients with mCRC were analyzed for KRAS mutations. Mutations in codon 12 and 13 were identified in 45 (33.3%) patients. Only 3 patients harbored a mutation of V600E. Compared with male patients, KRAS codon 12 mutations were more common in female patients (P<0.05). KRAS codon 13 mutations tended to arise in right-sided compared with left-sided colon cancer (P<0.05). Survival analysis was performed in 101 patients receiving primary tumor resection. Compared with KRAS codon 12 wild-type, codon 12 mutations were markedly correlated with a poorer survival (log-rank P= 0.002). No prognostic significance was revealed in codon 13 mutations. In univariate analysis, mortality risk was significantly increased by subtypes of G12D and G12V [hazard ratio (HR) =2.313, 95% confidence interval (CI) =1. P=0.03; HR=2.621, P=0.04, respectively]. The results of the present study suggested that codon 12 mutations, in particular G12D and G12V, predicted a negative prognosis in Chinese patients with mCRC. These findings require further confirmation via prospective studies with larger samples.

show abstract

Section: Discussionmentioning

confidence: 99%

Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Präklinische Analysen unterstützen die unterschiedlichen Muster der Genmutation und Genexpression bei rechts-und linksseitigen Tumoren [1113,1114]. Als Trennlinie wird in der Mehrzahl der Untersuchungen die splenische Flexur betrachtet [1051,1053]. Prinzipiell würde man die Trennlinie zwischen rechts-und linksseitigen Tumoren zwischen den proximalen zwei Dritteln und dem distalen Drittel des Colon transversum ziehen.…”

Section: Relevanz Der Tumorlokalisation In Der Behandlung Von Ras Wilunclassified

“…Prinzipiell würde man die Trennlinie zwischen rechts-und linksseitigen Tumoren zwischen den proximalen zwei Dritteln und dem distalen Drittel des Colon transversum ziehen. Angesichts der retrospektiven Evaluationen wurde jedoch in der Mehrzahl der Untersuchungen aus pragmatischen Gründen die splenische Flexur als Trennlinie betrachtet [1051,1053] …”

Section: Relevanz Der Tumorlokalisation In Der Behandlung Von Ras Wilunclassified

S3-Leitlinie – Kolorektales Karzinom

Schmiegel

Buchberger

Follmann³

et al. 2017

Z Gastroenterol

Self Cite

132

View full text Add to dashboard Cite

“…A study looking at the influence of ptl in the population of the crystal trial was recently published 18 . Baseline characteristics in the patients with lcc were relatively balanced; however, in patients with rcc, several differences between the treatment groups appeared to favour the folfiri arm.…”

Section: First Linementioning

confidence: 99%

“…A retrospective analysis looking at the effect of ptl in that trial was recently published in JAMA Oncology 18 . Among patients with lcc, the median os duration was significantly longer for those treated with folfiri plus cetuximab than for those treated with folfiri plus bevacizumab (38.3 months vs. 28.0 months; hr: 0.63; p = 0.002).…”

Section: Impact Of Ptl On Therapy With Either Egfr Mabs or Bevacizumabmentioning

confidence: 99%

The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement

et al. 2017

View full text Add to dashboard Cite

In recently published data, the predictive value of primary tumour location for the treatment of metastatic colorectal cancer with available biologic therapies has been explored. Recognizing the potential effect of those data on clinical practice, we convened a meeting of Canadian experts who treat metastatic colorectal cancer to develop a set of national, evidence-based treatment guidelines based on primary tumour location. This report summarizes the relevant evidence and presents the consensus recommendations of those experts.

show abstract

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer

Abstract: clinicaltrials.gov Identifiers: CRYSTAL, NCT00154102, and FIRE-3, NCT00433927.

Cited by 574 publications

References 26 publications

Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer

Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer

S3-Leitlinie – Kolorektales Karzinom

The Predictive Effect of Primary Tumour Location in the Treatment of Metastatic Colorectal Cancer: A Canadian Consensus Statement

Contact Info

Product

Resources

About